SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on May 8, 2003; DOI 10.1182/blood-2003-01-0189. This Article Full Text (PDF) All Versions of this Article: 2003-01-0189v1 102/5/1927    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Corradini, P. Articles by Gahrton, G. Search for Related Content PubMed PubMed Citation Articles by Corradini, P. Articles by Gahrton, G. Social Bookmarking                   What's this? Submitted January 22, 2003 Accepted April 4, 2003 Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in multiple myeloma Paolo Corradini*, Michele Cavo, Henk Lokhorst, Giovanni Martinelli, Carolina Terragna, Ignazio Majolino, Pinuccia Valagussa, Mario Boccadoro, Diana Samson, Andrea Bacigalupo, Nigel Russell, Vittorio Montefusco, Claudia Voena, and Gosta Gahrton Hematology - BMT Unit, Istituto Nazionale dei Tumori, University of Milano, Milano, Italy Hematology, Istituto Seragnoli, University of Bologna, Bologna, Italy Hematology, University Medical Center, Utrecht, The Netherlands Hematology, Ospedale San Camillo, Roma, Italy Hematology, University of Torino, Torino, Italy Hematology, Imperial College School of Medicine, Hammersmith Hospital, London, United Kingdom Hematology, Ospedale San Martino, Genova, Italy Hematology, Nottingham City Hospital, Nottingham, United Kingdom Hematology, Hiddinge University Hospital, Huddinge, Sweden * Corresponding author; email: paolo.corradini{at}istitutotumori.mi.it. Seventy patients in complete clinical remission after myeloablative allogeneic stem cell transplantation (allo-SCT) were enrolled in a longitudinal study to assess the predictive value of molecular monitoring. Using PCR for immunoglobulin gene rearrangements it was possible to generate a clone-specific molecular marker in 48 of the 70 patients. Sixteen of these patients (33%) attained durable PCR-negativity post-transplant, while 13 (27%) remained persistently PCR-positive and 19 (40%) showed a mixed pattern. The cumulative risk of relapse at 5 years was 0% for PCR-negative patients, 33% for PCR-mixed patients and 100% for PCR-positive patients. Within the group studied it was not possible to identify any clinical feature predictive of durable PCR-negativity. We believe that these findings could prompt the design of prospective studies to evaluate if the treatment of molecular disease can extend remission duration and survival. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J.-L. Harousseau, H. Avet-Loiseau, M. Attal, C. Charbonnel, F. Garban, C. Hulin, M. Michallet, T. Facon, L. Garderet, G. Marit, et al. Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: Long-Term Analysis of the IFM 99-02 and 99-04 Trials J. Clin. Oncol., December 1, 2009; 27(34): 5720 - 5726. [Abstract] [Full Text] [PDF] J.-L. Harousseau, M. Attal, and H. Avet-Loiseau The role of complete response in multiple myeloma Blood, October 8, 2009; 114(15): 3139 - 3146. [Abstract] [Full Text] [PDF] F. Morschhauser, M. Dreyling, A. Rohatiner, F. Hagemeister, and A. Bischof Delaloye Rationale for Consolidation to Improve Progression-Free Survival in Patients with Non-Hodgkin's Lymphoma: A Review of the Evidence Oncologist, October 1, 2009; 14(suppl_2): 17 - 29. [Abstract] [Full Text] [PDF] B. Bruno, M. Rotta, F. Patriarca, D. Mattei, B. Allione, F. Carnevale-Schianca, R. Sorasio, A. Rambaldi, M. Casini, M. Parma, et al. Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo Blood, April 2, 2009; 113(14): 3375 - 3382. [Abstract] [Full Text] [PDF] G. Gahrton and B. Bjorkstrand Allogeneic transplantation in multiple myeloma Haematologica, September 1, 2008; 93(9): 1295 - 1300. [Full Text] [PDF] A. C. Rawstron, A. Orfao, M. Beksac, L. Bezdickova, R. A. Brooimans, H. Bumbea, K. Dalva, G. Fuhler, J. Gratama, D. Hose, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders Haematologica, March 1, 2008; 93(3): 431 - 438. [Abstract] [Full Text] [PDF] D. Atanackovic, Y. Cao, T. Luetkens, J. Panse, C. Faltz, J. Arfsten, K. Bartels, C. Wolschke, T. Eiermann, A. R. Zander, et al. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation Haematologica, March 1, 2008; 93(3): 423 - 430. [Abstract] [Full Text] [PDF] W. Bensinger Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Drugs J. Clin. Oncol., January 20, 2008; 26(3): 480 - 492. [Abstract] [Full Text] [PDF] J. A. Katzel, P. Hari, and D. H. Vesole Multiple Myeloma: Charging Toward a Bright Future CA Cancer J Clin, September 1, 2007; 57(5): 301 - 318. [Abstract] [Full Text] [PDF] A. Dispenzieri, S. V. Rajkumar, M. A. Gertz, M. Q. Lacy, R. A. Kyle, P. R. Greipp, T. E. Witzig, J. A. Lust, S. J. Russell, S. R. Hayman, et al. Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement Mayo Clin. Proc., March 1, 2007; 82(3): 323 - 341. [Abstract] [Full Text] [PDF] N. Kroger, A. Badbaran, E. Holler, J. Hahn, G. Kobbe, M. Bornhauser, A. Reiter, T. Zabelina, A. R. Zander, and B. Fehse Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis Blood, February 1, 2007; 109(3): 1316 - 1321. [Abstract] [Full Text] [PDF] M.-V. Mateos, J.-M. Hernandez, M.-T. Hernandez, N.-C. Gutierrez, L. Palomera, M. Fuertes, J. Diaz-Mediavilla, J.-J. Lahuerta, J. de la Rubia, M.-J. Terol, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study Blood, October 1, 2006; 108(7): 2165 - 2172. [Abstract] [Full Text] [PDF] H. Lokhorst No RIC in high-risk myeloma? Blood, May 1, 2006; 107(9): 3420 - 3421. [Full Text] [PDF] M. A. Gertz Allo attack on amyloidosis Blood, March 15, 2006; 107(6): 2213 - 2214. [Full Text] [PDF] M. S. Raab, F. W. Cremer, I. N. Breitkreutz, S. Gerull, T. Luft, A. Benner, M. Goerner, A. D. Ho, H. Goldschmidt, and M. Moos Molecular monitoring of tumour load kinetics predicts disease progression after non-myeloablative allogeneic stem cell transplantation in multiple myeloma Ann. Onc., April 1, 2005; 16(4): 611 - 617. [Abstract] [Full Text] [PDF] N. Kroger, A. Shimoni, M. Zagrivnaja, F. Ayuk, M. Lioznov, H. Schieder, H. Renges, B. Fehse, T. Zabelina, A. Nagler, et al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma Blood, November 15, 2004; 104(10): 3361 - 3363. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020